Neurotech International Ltd

We're pleased to present our activities report for the quarter ended 30 September 2024 (Q1 FY2025), together with our Appendix 4C Quarterly Cash Flow Report. View the full report below. 👇

Neurotech’s Annual General Meeting will be held on Wednesday, 20 November 2024 at 9:00am AEDT at the offices of BDO Australia, located at Collins Square, Tower 4, Level 18, 727 Collins St, Docklands VIC. If you are unable to attend in person, you can vote online or submit a proxy form by 9:00am AEDT on Monday, 18 November 2024. Questions can also be submitted in advance by 12 November 2024. For more details, visit: neurotechinternational.com View the Notice of AGM / Proxy Form here: https://lnkd.in/gNbvvxm6 #NeurotechAGM #InvestorUpdates #ASX #CorporateGovernance #AGM2024 #Neurotech #NTI #AGM

During this #RettSyndromeAwareness month, we continue our mission to find effective treatments for Rett syndrome. Neurotech’s NTI164 has demonstrated significant clinical improvements in our trials, offering new hope for families. While there is no cure yet, our work is focused on bringing life-changing therapies to those who need them most. Together, we can bridge the gap towards a better life for those with Rett syndrome. #RettSyndrome #RettAwareness #NTI164 #ClinicalTrials #HealthcareInnovation #HopeForRett

Rett Syndrome is a rare, debilitating neurological disorder that affects almost every aspect of life. Most children with Rett develop normally for the first 6 to 18 months before losing abilities, including the ability to speak, walk, and even breathe. It impacts communication, hand use, and coordination, leaving individuals trapped in their bodies. At Neurotech, our NTI164 treatment is showing promise in improving key symptoms and quality of life for those affected. October is Rett Syndrome Awareness Month—a time to support research and work towards better treatments. #RettSyndrome #RettAwarenessMonth #NTI164 #RareDisease #NeurologicalDisorders #HopeForRett #NTI #Neurotech

An excellent medical discussion followed Associate Professor Carolyn Ellaway's presentation on NTI164 at the 9th World Rett Syndrome Congress. The panel, featuring top experts in Rett syndrome, explored both approved and emerging therapies that are shaping the future of treatment. 📷 Associate Professor Carolyn Ellaway is seated second from the right. #RettSyndrome #NTI164 #ClinicalTrials #EmergingTherapies #Neurotech #NTI #WorldRettCongress #MedicalResearch #HealthcareInnovation #GoldCoast

A big thank you to Associate Professor Carolyn Ellaway for her presentation at the 9th World Rett Syndrome Congress on the Gold Coast. Her talk, "A novel full-spectrum medicinal cannabis-derived clinical trial in Rett syndrome," shared our Phase I/II trial data for NTI164. We’re proud to be at the forefront of research that aims to make a meaningful difference for those living with Rett Syndrome. #RettSyndrome #NTI164 #ClinicalTrials #Neurotech #WorldRettCongress #HealthcareInnovation #MedicalResearch #GoldCoast #Neurotech #NTI

Day 1 of the 9th World Rett Syndrome Congress kicks off on the Gold Coast. We're looking forward to Associate Professor Carolyn Ellaway’s presentation on Friday, 4 October at 8:50 am AEST, where she’ll present on our Phase I/II trial data on NTI164, titled "A novel full-spectrum medicinal cannabis-derived clinical trial in Rett syndrome." For more information and to register, visit: rettworldcongress.org #Neurotech #NTI #NTI164 #RettSyndrome #ClinicalTrials #GoldCoast #WorldRettCongress #HealthcareInnovation #MedicalResearch #RettAssocationAustralia #Conference

October is Rett Syndrome Awareness Month, a time to shine a light on this debilitating neurological disorder that affects nearly every aspect of life. At Neurotech International (ASX: NTI), we’re committed to advancing research to improve the lives of patients with Rett syndrome. Our Phase I/II clinical trial of NTI164, a novel treatment, has shown significant improvements in communication, anxiety, and socialisation, with 93% of patients experiencing improvements in communication, anxiety, and socialisation. We are focused on finding innovative ways to help individuals with Rett syndrome and their families. Together, we can raise awareness and continue the search for more effective treatments. Learn more about our clinical trials at https://lnkd.in/dC35qwTi. Learn more about Rett Syndrome and how you can help: https://lnkd.in/eYkREQUr #RettSyndromeAwareness #Neurotech #NTI #NTI164 #RettSyndrome #ClinicalTrials #HopeForRett #HealthcareInnovation #MedicalResearch #OctoberAwareness #RettSyndrome

We’re delighted to announce that Neurotech International Ltd will be attending the 9th World Rett Syndrome Congress on the Gold Coast from 2-5 October, 2024. Associate Professor Carolyn Ellaway will present on our Phase I/II trial data on NTI164 in her talk titled "A novel full-spectrum medicinal cannabis-derived clinical trial in Rett syndrome" on Friday, 4 October at 8:50 am AEST. This presentation will cover the significant clinical benefits observed in Rett syndrome patients, with 93% showing improvements in key areas such as communication, anxiety, and socialisation. For more information and to register, visit: rettworldcongress.org #Neurotech #NTI #NTI164 #RettSyndrome #ClinicalTrials #GoldCoast #WorldRettCongress #HealthcareInnovation #MedicalResearch #RettAssocationAustralia #Conference International Rett Syndrome Foundation The Rett Syndrome Association of Australia

Australia continues to prove its status as a global leader in clinical trials, generating $1.6 billion for the economy in 2022, according to MTPConnect. Neurotech is proud to have conducted four successful trials in Australia for NTI164, targeting paediatric neurological disorders like autism spectrum disorder (ASD), Rett Syndrome, and PANDAS/PANS. Read more: 👇https://lnkd.in/gMvjYHuj #Neurotech #NTI #NTI164 #ClinicalTrials #Biotech #ASX #PANDAS #PANS #RettSyndrome #Autism #MTPConnect #HealthcareInnovation #Australia